DBV Technologies Stock Shows a 10.64% Increase at Opening
DBV Technologies surged by 10.64% this Friday morning, moving from €3.81 to €4.21. This sharp rise is part of a marked acceleration over several weeks, with the stock already up 36.03% in seven days and 57.09% over three months. Since January, the increase has exceeded 12%, while over twelve months, the rise reaches 377.3%, far outpacing the CAC 40, which is slightly down by 0.15% this morning.
Technically, the stock is now well above its reference moving averages. The position at €4.21 places it significantly beyond the 50-day average (€2.93), indicating a strong short-term momentum, and well above the 200-day average (€2.10), reflecting a marked progression since the beginning of the year. The Relative Strength Index (RSI) stands at 66, a territory generally associated with short-term overextension, while the Chaikin Money Flow remains positive at 0.12, indicating that buying flows continue to dominate the trades despite the rapid progression. This setup translates into a persistent accumulation of buyers, even though the stock approaches resistance levels where consolidation may occur.
Volatility and Market Sensitivity
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The analysis of Bollinger Bands places the price between €2.69 and €3.87, a range that the stock has significantly exceeded, signaling increased volatility beyond usual parameters. The MACD remains slightly positive (line at €0.21 versus signal at €0.15), with a histogram of 0.06, indicating a moderate but present bullish momentum. The monthly volatility of 23.94% reflects the significant movements recorded in recent weeks. With a beta of -0.38, the stock shows an inverse sensitivity to the market, allowing it to progress when the index slightly declines, as is the case this morning.
SectorSanté · Biotechnologies · Vaccins et laboratoires de recherche›Biotechnologie
Context
Period
Period: 1T2026
Key reported figures
Revenue: 1M€dedollars
Net income: -47,6M€dedollars
Free cash flow: -49M€dedollars
Guidance from the release
Toute l'équipe de DBV démontre une focalisation et une rigueur exceptionnelles alors que nous abordons des étapes décisives au cours des prochains mois.
Risks mentioned
Augmentation significative des dépenses de R&D.
Perte nette en hausse à 47,6 millions de dollars.
Opportunities identified
Dépôt de la demande de licence biologique prévu pour 2026.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
